Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK2 | Q92630 | 16/20 | 0.83 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CDK7 | P50613 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CCNH | P51946 | 1/20 | 0.53 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30569700 | 1.00 | DYRK2 (0.83) | DYRK2CDK6CCNT1CDK4CCNA2 | |
| SCHEMBL30569698 | 0.92 | DYRK2 (0.73) | DYRK2CDK6PIM1 | |
| SCHEMBL26447967 | 0.92 | DYRK2 (0.73) | DYRK2CDK6PIM1 | |
| SCHEMBL26447980 | 0.91 | DYRK2 (1.00) | DYRK2CDK6PIM1 | |
| SCHEMBL30569701 | 0.91 | DYRK2 (1.00) | DYRK2CDK6PIM1 | |
| SCHEMBL26447973 | 0.90 | DYRK2 (0.82) | DYRK2CDK6 | |
| SCHEMBL32677358 | 0.90 | DYRK2 (0.82) | DYRK2CDK6 | |
| SCHEMBL28608862 | 0.86 | CDK6 (0.75) | DYRK2CDK6CCNT1CDK4CCNA2 | |
| SCHEMBL30569706 | 0.85 | DYRK2 (0.81) | DYRK2CDK6PIM1 | |
| SCHEMBL26447886 | 0.85 | DYRK2 (0.81) | DYRK2CDK6PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282864-B1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2025-08-13 | — | — | EP | disclosed |
| EP-4282864-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282864-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-112390793-B | CDK6/DYRK2 double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2021-04-27 | — | — | CN | disclosed |
| CN-112390793-A | CDK6/DYRK2 double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2021-02-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303553-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CDK6, DYRK2, CDK16 | DYRK2 2/4885CDK6 1/4885CCNT1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.